GlassScriptPhysician profile
Uday Ashwin Jani
NPI 1871548693
$5,719.46
in general payments reported to CMS, 2019-2025
35 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $424 · 2021: $1,182 · 2022: $488 · 2023: $858 · 2024: $515 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,098.31 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $590.49 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $482.09 | 2019-2025 | |
| Abbott Laboratories | $346.59 | 2019-2025 | Proclaim, Octrode, Freestyle Libre 3 |
| Amgen INC. | $326.40 | 2019-2024 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $296.91 | 2019-2023 | Trintellix |
| Amarin Pharma, INC. | $221.31 | 2020-2022 | |
| Lilly USA, LLC | $220.39 | 2019-2025 | Zepbound, Kisunla, Mounjaro |
| Glaxosmithkline, LLC. | $197.86 | 2019-2022 | |
| Abbvie INC. | $175.83 | 2019-2025 | |
| Menarini Silicon Biosystems, INC. | $171.20 | 2025 | |
| Exact Sciences Corporation | $149.58 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Medicure Pharma INC. | $143.53 | 2021-2023 | Zypitamag |
| Astellas Pharma US INC | $142.55 | 2019-2024 | Veozah, Myrbetriq |
| Radius Health, INC. | $119.56 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $116.97 | 2022-2023 | Wellbutrin, Aplenzin |
| Currax Pharmaceuticals LLC | $104.78 | 2021-2025 | Contrave, Onzetra Xsail |
| Genzyme Corporation | $102.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.75 | 2022 | |
| Mylan Specialty L.P. | $78.37 | 2024 | Yupelri |
| Intuitive Surgical, INC. | $77.03 | 2023 | Da Vinci Surgical System |
| Medtronic Vascular, INC. | $76.94 | 2019 | |
| Esperion Therapeutics, INC. | $61.79 | 2021-2022 | |
| Brainsway USA INC | $50.23 | 2025 | Deep Tms |
| Sanofi Pasteur INC. | $40.26 | 2019-2023 | |
| Eisai INC. | $38.29 | 2020-2021 | |
| Grifols USA, LLC | $35.60 | 2023 | Prolastin-C Liquid |
| Corcept Therapeutics | $32.49 | 2021-2022 | |
| Axsome Therapeutics, INC. | $19.83 | 2025 | Auvelity |
| Philips North America LLC | $18.86 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.72 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.00 | 2022 | |
| Acella Pharmaceuticals, LLC | $17.95 | 2025 | NP Thyroid 60 |
| Allergan, INC. | $15.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uday Jani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.